Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eletriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B known ✓ | P28222 | 9/20 | 1.00 |
| ▸ | HTR1D known ✓ | P28221 | 6/20 | 0.66 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 12/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eletriptan SCHEMBL10083479 | 1.00 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL29414096 | 1.00 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL798473 | 1.00 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL1556539 | 1.00 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL4431798 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL3713443 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL4233264 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL1068516 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL29244076 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL317370 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10797 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4734974-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | Mabewo Phytopharm AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-4681714-A2 | METHODS OF TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | MapLight Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| US-20250381175-A1 | COMPOUNDS FOR INCREASING NEURAL PLASTICITY | UNIV CALIFORNIA (US) | 2025-12-18 | — | — | US | claimed |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | APTARGROUP, INC. (US) | 2025-12-09 | — | — | US | claimed |
| US-5807571-A | Transdermal therapeutic systems for administering indole serotonin agonists | LTS LOHMANN THERAPIE-SYSTEME GMBH (DE) | 1998-09-15 | — | — | US | claimed |
| CN-1039322-C | Indole derivatives | PFIZER (US) | 1998-07-29 | — | — | CN | claimed |
| WO-1998002186-A1 | INCLUSION COMPLEX CONTAINING INDOLE SELECTIVE SEROTONIN AGONIST | FARMARC NEDERLAND B.V. (NL) | 1998-01-22 | — | — | WO | claimed |
| EP-0592438-B1 | INDOLE DERIVATIVES | PFIZER (US) | 1997-08-27 | — | — | EP | claimed |
| US-5618834-A | Indole derivatives in the treatment of emesis | PFIZER INC. (US) | 1997-04-08 | — | — | US | claimed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | claimed |
| EP-0714659-A2 | Indole derivatives in the treatment of emesis | Pfizer Limited (GB) | 1996-06-05 | — | — | EP | claimed |
| EP-0592438-A1 | INDOLE DERIVATIVES. | PFIZER (US) | 1994-04-20 | — | — | EP | claimed |
| CN-1062529-A | INDOLE DERIVATIVES | PFIZER (US) | 1992-07-08 | — | — | CN | claimed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | claimed |